8-K: Village Farms International Reports Q4 and Full Year 2024 Results, Highlights Profitable Growth Initiatives for 2025

Village Farms International announces its Q4 and full year 2024 financial results, showcasing an 18% increase in full year consolidated sales to $336.2 million and outlining strategies for profitable growth in 2025.

Summary

• Village Farms International reported its financial results for the fourth quarter and year ended December 31, 2024.
• Full year consolidated sales grew by 18% year-over-year, reaching $336.2 million.
• Canadian cannabis sales increased by 31% year-over-year, with retail branded sales up by 23%.
• The company maintained a leading market share in dried flower and pre-rolls in Canada.
• Full year consolidated cash flow from operations amounted to $10.3 million.
• Q4 consolidated sales grew by 11% year-over-year to $82.6 million.
• International sales saw a significant increase of 113% year-over-year in Q4, and are expected to triple in 2025.
• Adjusted EBITDA for Q4 was impacted by a $10.5 million non-cash inventory impairment related to non-flower cannabis products.
• Excluding the impairment, Q4 consolidated Adjusted EBITDA would have been $7.0 million.
• The company has broken ground on Phase II expansion in the Netherlands, which is expected to quintuple annual production capacity by Q4 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reports revenue growth and expansion initiatives, a significant inventory impairment negatively impacted EBITDA. The forward-looking statements are optimistic, but the current results are mixed.

Positives

• Full year consolidated sales showed strong growth, increasing by 18% to $336.2 million.
• Canadian cannabis sales experienced substantial growth, with a 31% year-over-year increase.
• The company holds leading market positions in key cannabis product categories in Canada.
• Full year consolidated cash flow from operations was positive at $10.3 million.
• International sales are growing rapidly, with a 113% increase in Q4 and expectations to triple in 2025.
• The company is expanding its production capacity in the Netherlands, which is expected to significantly increase output.
• Net loss improved 66% to ($8.6 million), or ($0.08) per share from ($25.5 million), or ($0.23) per share.

Negatives

• A $10.5 million non-cash impairment charge related to non-flower inventory negatively impacted Q4 Adjusted EBITDA.
• Consolidated adjusted EBITDA was ($3.5 million) compared with ($0.7 million).
• Cash flow from operations was (C$3.3 million) compared with (C$1.6 million).

Risks

• The company faces risks related to the integration of Rose into its consolidated business.
• Obtaining additional financing on acceptable terms is a potential risk.
• The company may face difficulties in achieving and/or maintaining profitability.
• Variability of product pricing poses a risk to financial performance.
• The company is subject to risks inherent in the cannabis, hemp, CBD, cannabinoids, and agricultural businesses.
• Existing and new governmental regulations could impact the company's operations.
• The company is vulnerable to rising energy costs and inflationary effects on costs of cultivation and transportation.

Future Outlook

The company believes it is well-positioned to execute and deliver a successful year of profitable growth in 2025 and beyond, with expectations to triple international medicinal export sales in 2025.

Management Comments

• Michael DeGiglio, President and Chief Executive Officer, stated that the results reflect a continuation of positive trends and efforts to align resources and inventory toward more profitable growth opportunities.
• Management is confident that they are starting 2025 with good momentum to execute their profitable growth strategy due to strong performance, an improved balance sheet, and a healthy inventory position.
• Management is pleased with the pace of international sales growth, driven by demand in Germany, Australia, and the UK.

Industry Context

Village Farms is positioning itself as a leader in the regulated cannabis market, expanding its international presence and optimizing its Canadian operations to improve efficiencies and profitability. The company is also leveraging its expertise in controlled environment agriculture to capitalize on opportunities in the cannabis and CBD categories.

Comparison to Industry Standards

• The document states that Pure Sunfarms is one of the single largest cannabis operations in the world, the lowest-cost greenhouse producer and one of Canada's best-selling brands.
• The company holds the #1 and #4 cultivars in the German market through third-party distributors.
• Balanced Health Botanicals is one of the leading CBD and hemp-derived brands and e-commerce platforms in the US.

Legal Proceedings

• The ongoing Administrative Law Judge (ALJ) hearings regarding the proposed rescheduling of marijuana from a Schedule I to a Schedule III drug under the Controlled Substances Act are currently stayed pending an interlocutory appeal granted by the ALJ to resolve the Company's alleged improper ex parte communications by DEA.

Stakeholder Impact

• Shareholders are impacted by the financial performance, including revenue growth and profitability.
• Employees are affected by operational improvements and expansion initiatives.
• Customers benefit from the launch of new products and the company's focus on quality.
• Suppliers are impacted by the company's supply agreements and production activities.

Next Steps

• The company will continue to optimize its Canadian Cannabis resources to improve operational efficiencies.
• The company will focus on completing the Phase II expansion at its Leli Holland subsidiary in the Netherlands.
• The company plans to continue expanding its international presence with additional export contracts.
• The company will continue to work to ensure a fair and transparent process regarding the proposed rescheduling of marijuana from a Schedule I to a Schedule III drug under the Controlled Substances Act.

Key Dates